PPIG and neuroblastoma: In the literature, cyclophosphamide-induced toxicity has been evaluated in patients with tumour malignancies other than neuroblastoma; therefore, our findings interpreting CYP polymorphisms and cyclophosphamide-related adverse reactions in pediatric patients with neuroblastoma appear to be the first.